IL147396A0 - 1,4,5,6,- tetrahydropyrimidine derivative as a vitronectin inhibitor - Google Patents

1,4,5,6,- tetrahydropyrimidine derivative as a vitronectin inhibitor

Info

Publication number
IL147396A0
IL147396A0 IL14739600A IL14739600A IL147396A0 IL 147396 A0 IL147396 A0 IL 147396A0 IL 14739600 A IL14739600 A IL 14739600A IL 14739600 A IL14739600 A IL 14739600A IL 147396 A0 IL147396 A0 IL 147396A0
Authority
IL
Israel
Prior art keywords
vitronectin inhibitor
tetrahydropyrimidine derivative
tetrahydropyrimidine
derivative
vitronectin
Prior art date
Application number
IL14739600A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL147396A0 publication Critical patent/IL147396A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12Nitrogen atoms not forming part of a nitro radical
    • C07D239/16Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14739600A 1999-07-21 2000-07-08 1,4,5,6,- tetrahydropyrimidine derivative as a vitronectin inhibitor IL147396A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99114372A EP1070707A1 (en) 1999-07-21 1999-07-21 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor
PCT/EP2000/006504 WO2001007417A1 (en) 1999-07-21 2000-07-08 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor

Publications (1)

Publication Number Publication Date
IL147396A0 true IL147396A0 (en) 2002-08-14

Family

ID=8238643

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14739600A IL147396A0 (en) 1999-07-21 2000-07-08 1,4,5,6,- tetrahydropyrimidine derivative as a vitronectin inhibitor

Country Status (29)

Country Link
US (1) US6900318B1 (cs)
EP (2) EP1070707A1 (cs)
JP (1) JP2003505450A (cs)
KR (1) KR20020063838A (cs)
CN (1) CN1361767A (cs)
AR (1) AR024794A1 (cs)
AT (1) ATE286030T1 (cs)
AU (1) AU775567B2 (cs)
BG (1) BG106322A (cs)
BR (1) BR0012554A (cs)
CA (1) CA2379086C (cs)
CZ (1) CZ200285A3 (cs)
DE (1) DE60017150D1 (cs)
EA (1) EA200200187A1 (cs)
EE (1) EE200200031A (cs)
HK (1) HK1048316A1 (cs)
HR (1) HRP20020057A2 (cs)
HU (1) HUP0201939A3 (cs)
IL (1) IL147396A0 (cs)
MX (1) MXPA02000674A (cs)
MY (1) MY133525A (cs)
NO (1) NO20020311L (cs)
NZ (1) NZ516233A (cs)
PL (1) PL353014A1 (cs)
SK (1) SK522002A3 (cs)
TR (1) TR200200116T2 (cs)
WO (1) WO2001007417A1 (cs)
YU (1) YU90201A (cs)
ZA (1) ZA200110361B (cs)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2186720T3 (es) * 1994-05-27 2003-05-16 Merck & Co Inc Composiciones para inhibir la reabsorcion osea mediada por osteoclastos.
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
BR9907735A (pt) * 1998-01-23 2000-10-17 Aventis Pharma Gmbh Derivados de sulfonamida como inibidores da reabsorção óssea e como inibidores da aderência celular
US6313119B1 (en) * 1998-01-23 2001-11-06 Adventis Pharma Deutschland Gmbh Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion

Also Published As

Publication number Publication date
CA2379086A1 (en) 2001-02-01
TR200200116T2 (tr) 2002-04-22
US6900318B1 (en) 2005-05-31
HUP0201939A3 (en) 2003-02-28
ZA200110361B (en) 2002-12-18
JP2003505450A (ja) 2003-02-12
WO2001007417A1 (en) 2001-02-01
CZ200285A3 (cs) 2003-02-12
EE200200031A (et) 2003-02-17
SK522002A3 (en) 2003-05-02
CN1361767A (zh) 2002-07-31
NO20020311D0 (no) 2002-01-21
NO20020311L (no) 2002-01-21
MY133525A (en) 2007-11-30
PL353014A1 (en) 2003-10-06
BG106322A (en) 2002-08-30
NZ516233A (en) 2004-07-30
YU90201A (sh) 2004-07-15
KR20020063838A (ko) 2002-08-05
EP1204646A1 (en) 2002-05-15
EP1070707A1 (en) 2001-01-24
ATE286030T1 (de) 2005-01-15
HUP0201939A2 (hu) 2002-12-28
CA2379086C (en) 2009-01-06
EP1204646B1 (en) 2004-12-29
MXPA02000674A (es) 2002-07-30
HRP20020057A2 (en) 2003-06-30
HK1048316A1 (zh) 2003-03-28
DE60017150D1 (de) 2005-02-03
AR024794A1 (es) 2002-10-23
AU775567B2 (en) 2004-08-05
AU6822600A (en) 2001-02-13
EA200200187A1 (ru) 2002-10-31
BR0012554A (pt) 2002-04-16

Similar Documents

Publication Publication Date Title
MXPA01013406A (es) Compuestos inhibidores de vla-4.
IL159332A0 (en) A knowledge-engineering protocol-suite
ZA200203834B (en) Adamantane derivatives.
AU4787301A (en) 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
AU142007S (en) A cafetiere
PT1571140E (pt) Derivados c-substituídos de ciclo-hexilmetilamina
HUP0201795A3 (en) Disinfectants
GB9903050D0 (en) A condenser
GB2389113B (en) B-secretase inhibitor
IL147396A0 (en) 1,4,5,6,- tetrahydropyrimidine derivative as a vitronectin inhibitor
GB9901266D0 (en) A bookend
GB2350361B (en) 3,4,5-tricyanophenyl derivatives
GB2346143B (en) A compound
ZA200109203B (en) VLA-4 inhibitor compounds.
GB2349386B (en) A compound
AU137661S (en) A bar stool
AU143449S (en) A bar
GB9906874D0 (en) A compound
GB9924784D0 (en) Imperial winlad
AU139405S (en) A furniture unit
GB9910695D0 (en) A hairband
GB9923771D0 (en) A powerfeed
GB9921309D0 (en) A pentapod
AU140877S (en) A frypan
AU140789S (en) A wallhanging